Long-term effectiveness, safety and prognostic factors of response to treatment with bimekizumab in patients with plaque psoriasis: results from a real-world multicentre study
In this multicentre observational retrospective study, bimekizumab demonstrated high effectiveness, together with a good safety profile, over a period of 78 weeks. The presence of psoriatic arthritis, obesity and longer disease duration seemed to influence response to treatment negatively in the mid term (24 weeks), while previous biologic exposure affected clinical outcomes in the long term (52 weeks).
Authors
- Irene Stefanaki (ORCID: https://orcid.org/0000-0002-2964-370X)
- Ioannis‐Alexios Koumprentziotis (ORCID: https://orcid.org/0000-0002-1156-7139)
- Fiori Kousta
- A. Befon
- Marina Papoutsaki (ORCID: https://orcid.org/0000-0002-2422-0994)
- Vasiliki Chasapi (ORCID: https://orcid.org/0000-0003-2168-3317)
- Αντώνιος Κανελλέας (ORCID: https://orcid.org/0000-0003-0779-7641)
- Natalia Rompoti (ORCID: https://orcid.org/0000-0002-9326-6726)
- Charitomeni Vavouli
- Evangelia Papadavid (ORCID: https://orcid.org/0000-0002-8634-102X)
- Maria Politou
- Kyriaki Lampadaki
- Sofia Theotokoglou (ORCID: https://orcid.org/0000-0002-9076-3866)
- Electra Nicolaidou (ORCID: https://orcid.org/0000-0002-8221-0217)
- Eleni Lazou
- Konstantinos Theodoropoulos (ORCID: https://orcid.org/0000-0001-6272-4459)
- M Tzaki
- Alexander Stratigos
- Pantelis Panagakis
Institutions
- National and Kapodistrian University of Athens (GR)
- Andreas Sygros Hospital (GR)
- Hospital Venereal and Skin Diseases Thessaloniki (GR)
Publication Details
- Journal
- Clinical and Experimental Dermatology
- Published
- 2025-11-05
- DOI
- https://doi.org/10.1093/ced/llaf492
- Primary Topic
- Psoriasis: Treatment and Pathogenesis
- Type
- article
- Field-Weighted Citation Impact
- 0.00